Sanara MedTech Inc. (SMTI) · Aug 11, 2026 · Earnings

Revenue and EPS missed benchmarks as costs and cash pressure rose

Revenue and EPS missed benchmarks as costs and cash pressure rose

The quarter came in below the standing benchmark. Sanara’s own prior Q2 revenue guide was $28.5 million–$29.5 million, while published consensus was approximately $28.95 million; actual revenue was $28.14 million, a shortfall versus both the midpoint and consensus. Published EPS consensus was approximately negative $0.03, versus reported continuing-operations EPS of negative $0.05.

MetricQ2 2026Q2 2025 / expectationRead
Net revenue$28.1M$25.8M prior year; $28.5M–$29.5M company guide; ~$28.95M consensus9% year-over-year growth, but below benchmarks (Financial Highlights; Revenue by product)
Gross margin93%92% prior yearFavorable mix and pricing (Financial Highlights; Income Statement)
Operating income$1.8M$2.5M prior yearLower despite higher revenue (Income Statement)
Continuing-operations EPS$(0.05)$0.05 prior year; approximately $(0.03) consensusMissed published expectation (Income Statement)
Adjusted EBITDA$5.0M$4.7M prior yearModest improvement, but below the pace of revenue growth (Adjusted EBITDA reconciliation)
Operating cash flow$(0.4)M first six months$0.7M provided prior yearCash generation deteriorated (Cash Flow statement)
Cash / long-term debt$15.4M / $46.5M$16.6M / $46.0M at December 31, 2025Less cash and slightly more debt (Balance Sheet)

Revenue growth remains real, but the quality of the quarter weakened. Soft-tissue repair revenue rose 11% to $25.2 million, more than offsetting an 8% decline in bone-fusion revenue to $2.9 million. Gross margin improved to 93%, yet operating expenses climbed 14%—faster than revenue—because of higher sales spending, compensation, and roughly $1.1 million of legal and advisory costs tied to strategic initiatives. That pushed operating income down 28% to $1.8 million (Revenue by product; Income Statement; Management discussion).

Adjusted EBITDA improved, but mostly preserves rather than expands operating leverage. Adjusted EBITDA increased only $0.3 million to $5.0 million despite $2.3 million of additional revenue. The result was helped by gross-margin expansion but restrained by higher SG&A; the company also excluded $1.1 million of acquisition and transaction-related costs from the measure (Adjusted EBITDA reconciliation). GAAP continuing operations consequently swung to a $0.4 million loss, with higher cash interest and equity-method investment losses adding pressure (Income Statement).

The balance-sheet signal is less comfortable than the headline growth rate. Sanara used $0.4 million of operating cash in the first half versus generating $0.7 million a year earlier, while cash fell to $15.4 million and long-term debt rose to $46.5 million. Management attributes the cash deterioration to commission timing and higher cash interest after the shift away from paid-in-kind interest; regardless, the filing shows that stronger EBITDA has not yet translated into stronger cash generation (Cash Flow statement; Balance Sheet).

The MIMEDX transaction is important context, but not new information in this release. The proposed acquisition was already announced after quarter-end and remains subject to closing conditions, so its mention does not materially change the quarter’s operating read. On the numbers, the filing is a mild miss: growth and margins are healthy, but revenue and EPS fell short of benchmarks, while expense growth and cash conversion moved in the wrong direction (Management commentary; Forward-looking statements).

Original filing on SEC EDGAR

More Sanara MedTech Inc. news

Revenue and EPS missed benchmarks as costs and cash pressure rose | SMTI Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.